SYSireesha Yedururi

Sireesha Yedururi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sireesha Yedururi has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contextual structured annotations on PACS: a futuristic vision for reporting routine oncologic imaging studies and its potential to transform clinical work and research

    by Vincenzo K. Wong, Mindy X. Wang, Eesha Bethi, Sindhu Nagarakanti, Ajaykumar C. Morani, Leonardo P. Marcal, Gaiane M. Rauch, Jeffrey J. Brown, Sireesha Yedururi

    Radiologists currently have very limited and time-consuming options to annotate findings on the images and are mostly limited to arrows, calipers and lines to annotate any type of findings on most PACS systems. We propose a framework placing encoded, transferable, highly contextual structured text annotations directly on PACS images indicating the type of lesion, level of suspicion, location, lesion measurement, and TNM status for malignant lesions, along with automated integration of this information into the radiology report. This approach offers a one-stop solution to generate radiology reports that are easily understood by other radiologists, patient care providers, patients, and machines while reducing the effort needed to dictate a detailed radiology report and minimizing speech recognition errors. It also provides a framework for automated generation of large volume high quality annotated data sets for machine learning algorithms from daily work of radiologists. Enabling voice dictation of these contextual annotations directly into PACS similar to voice enabled Google search will further enhance the user experience. Wider adaptation of contextualized structured annotations in the future can facilitate studies understanding the temporal evolution of different tumor lesions across multiple lines of treatment and early detection of asynchronous response/areas of treatment failure. We present a futuristic vision, and solution with the potential to transform clinical work and research in oncologic imaging.

  • Open Access

    Redifferentiation Effect of Larotrectinib for NTRK Fusion-Positive Pediatric Thyroid Cancer and Outcomes After Therapy

    by Luz E Castellanos, Sireesha Yedururi, Steven G Waguespack

    Context: Few data exist regarding larotrectinib therapy in pediatric NTRK fusion–positive papillary thyroid cancer (PTC), especially its effects on redifferentiation in radioactive iodine–refractory (RAIR) disease. Objective: To describe redifferentiation effects and disease outcomes in patients with stage 2 pediatric PTC following treatment with larotrectinib ± RAI. Methods: A retrospective case series at a tertiary cancer center of patients with NTRK fusion–positive pediatric PTC and RAIR pulmonary metastases treated with larotrectinib and considered for 131I therapy. Tumor response was assessed utilizing RECIST 1.1. Results: Four patients (aged 6-16 years at PTC diagnosis; 50% female) were treated with larotrectinib 100 mg twice a day for a median of 14 months (range 6-30 months). Treatment was well tolerated, except for grade 3 hypocalcemia in 1 patient with pre-existing hypoparathyroidism. All patients had tumor shrinkage (−25% to −100%) in target and nontarget pulmonary metastases. On diagnostic 123I thyroid scans, any RAI uptake was identified in only 2 patients, and therapeutic 131I did not cause further incremental tumor shrinkage in the patients treated, despite robust pulmonary uptake on the post-therapy scans. After stopping larotrectinib and with a mean follow-up of 38 months (range 26-48 months), 2 patients had stable disease and 2 had clinically insignificant tumor progression. Conclusion: Although larotrectinib can have a redifferentiation effect in pediatric NTRK fusion-positive PTC, therapy with 131I may not lead to an incremental benefit in established RAIR disease. Significant structural disease progression did not occur after cessation of larotrectinib, suggesting that a drug holiday can safely be considered in this population.


  • Necrotizing Pancreatitis Related to Immune Checkpoint Inhibitor Therapy

    by Sidra Naz, Sireesha Yedururi, Yinghong Wang, Suresh Chari, Anusha S. Thomas

  • Pancreatitis Related to Immune Checkpoint Inhibitor Therapy

    by Sidra Naz, Sireesha Yedururi, Yinghong Wang, Suresh Chari, Anusha S. Thomas

  • Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer

    by Deepak Bhamidipati, Sireesha Yedururi, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Vivek Subbiah


  • Imaging Response Evaluation

    by Sireesha Yedururi, Usama I. Salem, Rony Avritscher, Evelyne M. Loyer

  • Open Access

    Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition

    by Niamh Coleman, Vivek Subbiah, Shubham Pant, Keyur Patel, Sinchita Roy-Chowdhuri, Sireesha Yedururi, Amber Johnson, Timothy A. Yap, Jordi Rodon, Kenna Shaw, et al.

    Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selection and allow for the development of rationally designed next-line or combination treatment strategies and improved patient outcomes. AKT is a critical effector of the phosphoinositide 3-kinase signaling cascade, one of the most commonly activated pathways in human cancer. Deregulation of signaling pathways, such as RAF/MEK/ERK are previously described mechanisms of resistance to AKT/PI3K inhibitors. Mutations in the mTOR gene, however, are exceedingly rare. We present a case of acquired mTOR resistance, following targeted AKT inhibition, and subsequent response to mTOR1/2 inhibitor in a patient with metastatic endometrial cancer, the first documented response to ATP-competitive mTOR inhibition in this setting. This case supports mTOR mutation as a mechanism of resistance, and underscores the importance of tumor molecular profiling, exemplifying precision medicine in action.


  • Open Access

    Imaging of Neuroendocrine Prostatic Carcinoma

    by Ahmed Taher, Corey T. Jensen, Sireesha Yedururi, Devaki Shilpa Surasi, Silvana C. Faria, Tharakeshwar K. Bathala, Bilal Mujtaba, Priya Bhosale, Nicolaus Wagner-Bartak, Ajaykumar C. Morani

    Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration-resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.


  • Temporal evolution of metastatic disease: part I—an in-depth review of the evolution of metastatic disease across diverse spectrum of non-neural solid tumors on serial oncologic imaging studies and relevant practical applications

    by Nahyun Jo, Leonardo Marcal, Venkata Subbiah Katabathina, Ajaykumar C. Morani, Medhini Rachamallu, Srinivasa Prasad, Sireesha Yedururi

    With improved survival rates of patients with metastatic disease due to continuously evolving multimodality treatment options, radiologists are increasingly interpreting imaging studies from patients with protracted metastatic disease. It is thus crucial for radiologists to have an in-depth understanding of the temporal evolution of metastatic spread and the accompanying findings on imaging studies, to provide accurate interpretation that supports optimal management. A general overview of the evolution of cancer spread on serial imaging studies and common pathways of tumor spread across multiple tumor types and tumor locations is not readily available in radiology literature. The key common pathways of tumor spread across diverse spectrum of tumors relevant to radiologists are summarized in a logical schematic approach which focusses on aiding radiologists to understand the pathways of spread resulting in current sites of metastatic disease involvement and then to potentially predict future sites of metastatic involvement. This article also summarizes the practical applications of this knowledge to the routine oncologic imaging interpretation.


  • Temporal evolution of metastatic disease: part II—a novel proposal for subcategorization of metastatic disease from non-neural solid tumors with diverse histologies and locations

    by Sireesha Yedururi, Leonardo Marcal, Ajaykumar C. Morani, Venkata Subbiah Katabathina, Nahyun Jo, Medhini Rachamallu, Srinivasa Prasad

    Tumor spread is a continuous process and metastases can further disseminate. Currently, metastatic disease from most primary tumors is subcategorized as M0 if absent and M1 if present. However, metastatic disease in different locations may have different prognostic implications, even if it is from the same primary tumor. The current staging systems for metastatic disease have not evolved to match our understanding of the disease’s evolution or the evolving treatment paradigms. Primary tumor-specific subcategorization of metastatic disease is currently available for a few tumors, but not all of them imply further remote spread of tumor, similar to tumor (T) and N (node) subcategorizations of the TNM staging, nor are they applicable to wide spectrum of other tumors. In this era of precision medicine, tumor-type agnostic therapies based on common biomarkers rather than primary tumor sites are emerging, but a subcategorization system applicable to metastatic disease from diverse primary tumor locations and with diverse histologies is not available. In this article, we discuss the need to further classify the metastatic disease and present a subcategorization applicable to metastatic disease from non-neural solid tumors from different primary tumor sites and with different histologies, which is based on the temporal spread of metastatic disease. Our proposed subcategorization scheme for metastatic disease into M0, M1, M2 and M3, is universally applicable to a diverse spectrum of non-neural solid tumors, and increasing M subcategorization represents further remote spread of tumor.